drugset / Trial / NCT01249274

Progesterone for Postpartum Cocaine Relapse

NCT01249274 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators propose a placebo-controlled, randomized clinical trial that would enroll 50 postpartum women with a history of cocaine abuse or dependence to assess whether progesterone (100mgs twice daily) decreases postpartum cocaine use.

Timeline

Start
2011-02
Primary completion
2013-07
Completion
2013-07

Outcome

Mixed primary results

registry MEAN Placebo: Week 12: 0.70 (Standard Deviation 2.11) number of days per week of cocaine use NCT01249274 ↗

registry MEAN Progesterone: Week 12: 0.24 (Standard Deviation 0.68) number of days per week of cocaine use NCT01249274 ↗

registry analysis (superiority or other test); Placebo vs Progesterone; p = 0.010; Risk Ratio (RR) 1.19 (95% CI 1.04 to 1.36); Generalized Estimating Equation NCT01249274 ↗

registry MEAN Placebo: End of Trial (Week 12): 0.2860 (0.1237 to 0.6609) days of cocaine use between visits NCT01249274 ↗

registry MEAN Progesterone: End of Trial (Week 12): 0.05550 (0.009978 to 0.3087) days of cocaine use between visits NCT01249274 ↗

registry analysis (superiority or other test); Placebo vs Progesterone; p = 0.003; Risk Ratio (RR) 30.39 (95% CI 3.18 to 290.04); Generalized Estimating Equation NCT01249274 ↗

registry analysis (superiority or other test); Placebo vs Progesterone; p = 0.038; Risk Ratio (RR) 16.65 (95% CI 1.18 to 235.52); Generalized Estimating Equation NCT01249274 ↗

registry analysis (superiority or other test); Placebo vs Progesterone; p = 0.99; Risk Ratio (RR) 1.00 (95% CI 0.87 to 1.15); Generalized Estimating Equation NCT01249274 ↗

registry analysis (superiority or other test); Placebo vs Progesterone; p = 0.75; Risk Ratio (RR) 1.34 (95% CI 0.23 to 7.88); Generalized Estimating Equation NCT01249274 ↗

registry analysis (superiority or other test); Placebo vs Progesterone; p = 0.84; Risk Ratio (RR) 1.18 (95% CI 0.24 to 5.84); Generalized Estimating Equation NCT01249274 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 100 mg —